Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Authors: Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Young Joung, Jae, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, Zohren, Fabian, Fizazi, Karim

Source: Lancet. 402(10398):291-303

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100195578183.0x000001&indx=1&recIds=ETOCvdc_100195578183.0x000001

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma

Authors: Grivas, Petros, Kopyltsov, Evgeny, Su, Po-Jung, Parnis, Francis X., Park, Se Hoon, Yamamoto, Yoshiaki, Fong, Peter C., Tournigand, Christophe, Climent Duran, Miguel A., Bamias, Aristotelis, Caserta, Claudia, Chang, Jane, Cislo, Paul, di Pietro, Alessandra, Wang, Jing, Powles, Thomas

Source: European urology. 83(4):320-328

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185967232.0x000001&indx=1&recIds=ETOCvdc_100185967232.0x000001

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Authors: O'Malley, David M., Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., Swisher, Elizabeth M., Maloney, Lara, Goble, Sandra, Lin, Kevin K., Kwan, Tanya, Ledermann, Jonathan A., Coleman, Robert L.

Source: In Gynecologic Oncology December 2022 167(3):404-413

Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.

Authors: Fizazi, Karim, Azad, Arun A, Matsubara, Nobuaki, Carles, Joan, Fay, Andre P, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, Laird, A Douglas, Zohren, Fabian

Source: Future Oncology; Mar2025, Vol. 21 Issue 6, p637-652, 16p

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Authors: Clamp, Andrew R ¹, Lorusso, Domenica ^{2, *}, Oza, Amit M ³, Aghajanian, Carol ⁴, Oaknin, Ana ⁵, Dean, Andrew ⁶, Colombo, Nicoletta ⁷, Weberpals, Johanne I ⁸, Scambia, Giovanni ⁹, Leary, Alexandra ¹⁰, Holloway, Robert W ¹¹, Amenedo Gancedo, Margarita ¹², Fong, Peter C ¹³, Goh, Jeffrey C ^{14, 15}, O’Malley, David M ¹⁶, Armstrong, Deborah K ¹⁷, Banerjee, Susana ¹⁸, García-Donas, Jesus ¹⁹, Swisher, Elizabeth M ²⁰, Cameron, Terri ²¹, Goble, Sandra ²², Coleman, Robert L ²³, Ledermann, Jonathan A ²⁴

Source: In International Journal of Gynecological Cancer July 2021 31(7):949-958

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Authors: Oaknin, Ana, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Amenedo Gancedo, Margarita, Fong, Peter C., Goh, Jeffrey C., O'Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García‐Donas, Jesus, Swisher, Elizabeth M., Cameron, Terri, Maloney, Lara, Goble, Sandra, Ledermann, Jonathan A., Coleman, Robert L.

Source: Cancer medicine. 10(20):7162-7173

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132332961.0x000001&indx=1&recIds=ETOCvdc_100132332961.0x000001

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.

Authors: Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, Zohren, Fabian

Source: Future Oncology; 2024, Vol. 20 Issue 29, p2123-2135, 13p

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Authors: Colombo, Nicoletta, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O'Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Meunier, Juliette, Cameron, Terri, Maloney, Lara, Goble, Sandra, Bedel, Josh, Ledermann, Jonathan A., Coleman, Robert L.

Source: In Gynecologic Oncology October 2020 159(1):101-111

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Authors: Ledermann, Jonathan A ^*, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew R, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Maloney, Lara, Goble, Sandra, Coleman, Robert L

Source: In The Lancet Oncology May 2020 21(5):710-722

Clinical and serological resolution of pembrolizumab associated Sjögren's syndrome: long-term follow-up

Authors: Clark, Hadleigh J, Fong, Peter C C, Ng, Kristine P L

Source: Rheumatology. 61(1):e22-e24

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100138792540.0x000001&indx=1&recIds=ETOCvdc_100138792540.0x000001

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A

Source: In The Lancet 28 October-3 November 2017 390(10106):1949-1961

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Authors: Marth, Christian, Vergote, Ignace, Scambia, Giovanni, Oberaigner, Willi, Clamp, Andrew, Berger, Regina, Kurzeder, Christian, Colombo, Nicoletta, Vuylsteke, Peter, Lorusso, Domenica, Hall, Marcia, Renard, Vincent, Pignata, Sandro, Kristeleit, Rebecca, Altintas, Sevilay, Rustin, Gordon, Wenham, Robert M., Mirza, Mansoor Raza, Fong, Peter C., Oza, Amit, Monk, Bradley J., Ma, Haijun, Vogl, Florian D., Bach, Bruce A.

Source: In European Journal of Cancer January 2017 70:111-121

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Authors: Konecny, Gottfried E, Finkler, Neil, Garcia, Agustin A, Lorusso, Domenica, Lee, Paula S, Rocconi, Rodney P, Fong, Peter C, Squires, Matt, Mishra, Kaushal, Upalawanna, Allison, Wang, Yongyu, Kristeleit, Rebecca

Source: In The Lancet Oncology June 2015 16(6):686-694

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Authors: Saad, Fred, Fizazi, Karim, Jinga, Viorel, Efstathiou, Eleni, Fong, Peter C, Hart, Lowell L, Jones, Robert, McDermott, Raymond, Wirth, Manfred, Suzuki, Kazuhiro, MacLean, David B, Wang, Ling, Akaza, Hideyuki, Nelson, Joel, Scher, Howard I, Dreicer, Robert, Webb, Iain J, de Wit, Ronald

Source: In The Lancet Oncology March 2015 16(3):338-348

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A

Source: Lancet. 390(10106):1949-1961

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100131225516.0x000001&indx=1&recIds=ETOCvdc_100131225516.0x000001

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Authors: Fizazi, Karim, Azad, Arun A., Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C. C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, A. Douglas, Zohren, Fabian, Agarwal, Neeraj

Source: Nature Medicine; January 2024, Vol. 30 Issue: 1 p257-264, 8p

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Authors: Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C., Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D., Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P., Rey, Felipe

Source: Journal of Clinical Oncology; 8/1/2023, Vol. 41 Issue 22, p3839-3850, 12p

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer

Authors: Molife, L Rhoda, Omlin, Aurelius, Jones, Rob J, Karavasilis, Vasilios, Bloomfield, David, Lumsden, Graeme, Fong, Peter C, Olmos, David, O'Sullivan, Joe M, Pedley, Ian, Hickish, Tamas, Jenkins, Peter, Thompson, Emilda, Oommen, Nikhil, Wheatley, Duncan, Heath, Catherine, Temple, Graham, Pelling, Katy, de Bono, Johann S

Source: Future oncology. 10(2):219-231

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100115602420.0x000001&indx=1&recIds=ETOCvdc_100115602420.0x000001

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.

Authors: Fong, Peter C., Boss, David S., Yap, Timothy A.

Source: New England Journal of Medicine; July 9 2009, Vol. 361 Issue 2, p123-134, 12p

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.

Authors: Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O'Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Cella, David

Source: Journal of Clinical Oncology; 10/20/2020, Vol. 38 Issue 30, p3494-3505, 19p